Clinical Trials Logo
  1. Home
  2. Clostridium Infections
  3. NCT00384527

Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease

Clostridium Infections Clinical Trial

Official title:
Multicenter, Double-blind Study of Nitazoxanide Compared to Vancomycin in the Treatment of Clostridium Difficile-associated Disease

Clinical Trial Summary

The primary objective of the study is to demonstrate non-inferiority of nitazoxanide compared to vancomycin in resolving symptoms of Clostridium difficile-associated disease (CDAD).

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00384527
Study type Interventional
Source Romark Laboratories L.C.
Contact
Status Terminated
Phase Phase 3
Start date December 2006
Completion date October 2007
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04179201 - Study on Clostridium Difficile Infection in Chinese Patients With Inflammatory Bowel Disease
Completed NCT02563106 - A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI Phase 2
Completed NCT00214461 - Safety, Tolerability, and Immunogenicity of a Clostridium Difficile Toxoid Vaccine in Healthy Elderly Volunteers Phase 1
Completed NCT00314951 - Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) Phase 3
Completed NCT00328263 - Efficacy and Safety of BIO-K + CL1285 in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Patients Phase 3
Completed NCT00127803 - Safety, Tolerability, and Immunogenicity Study of a Clostridium Difficile Toxoid Vaccine in Healthy Adult Volunteers Phase 1
Completed NCT00350298 - Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease Phase 2
Withdrawn NCT05077085 - Bezlotoxumab Versus FMT for Multiple Recurrent CDI Phase 4
Recruiting NCT02681068 - MicroTrans - A Multicenter Registry of Fecal Microbiota Transplantation N/A
Completed NCT00446355 - Clinical Outcomes of Patients With Clostridium Difficile Associated Disease Attributable to Diverse tcdC Genotypes N/A
Completed NCT00269399 - A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) Phase 3
Completed NCT04026009 - Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years Phase 1
Recruiting NCT06277999 - C.Difficile Observational Study
Completed NCT00468728 - PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) Phase 3